NeOnc Technologies Holdings is trading 5.29% down now at $4.12 after opening-day weakness on August 12, 2026; the immediate cause remains unclear.
- The company reported encouraging NEO100 Phase 2a results, including 48.9% six-month progression-free survival versus a 20% benchmark.
- Median overall survival was 26.09 months.
- Available coverage does not explicitly connect the decline to the announcement, while broader markets are higher.